What happened Shares of Dexcom (NASDAQ: DXCM), a leader in the growing market for blood sugar trackers, jumped 47.4% in November, according to data from S&P Global Market Intelligence. Another quarterly report filled with positive signals was the spark that started the rally. So what Glucose monitors that sync with smartphones are gaining popularity fast, and Dexcom's third-quarter earnings report suggests its G6 system is leading the pack. Compared with the prior-year period, revenue grew 49% to $396 million. Beneath the top line, it looks like the company's easy-to-use solutions are flying off shelves all by themselves. Third-quarter operating expenses rose just 23% to $191 million. Image source: Getty Images. Dexcom also raised its expectations for the rest of 2019. Instead of a range of $1.33 billion to $1.38 billion, total revenue is expected to reach between $1.43 billion and $1.45 billion this year. On the bottom line, adjusted operating earnings are expected to reach 9% of total sales instead of the 7% operating margin the company had been expecting just a few months earlier. Now what There's no shortage of glucose monitoring options for diabetes patients to choose from, but Dexcom's devices could command a leading share of the market for the foreseeable future. In October, the company officially started selling everything needed to begin using a G6 to Medicare patients in partnership with Walgreens. Keeping glucose levels in a normal range has been shown to reduce the risk of problems common among diabetes patients, such as vision loss. That means Medicare can save a bundle over the long run by providing Dexcom's devices. 10 stocks we like better than DexComWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source